In the Margins
In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.
Most Read
The very first independent chair we profiled for FBV was Leigh Wilson at Victory Funds, for our A Seat at the Table section. Victory Capital Management had recently redefined itself ...
The Securities and Exchange Commission's move earlier this week to greenlight Dimensional Fund Advisors' plan to offer ETF share classes of its mutual funds is likely ...
After years of making gains in filling fund board seats, women and individuals representing minority groups lost significant ground in the most recent two-year period measured ...
Mutual fund independent directors earned more in 2024 than in the year prior, and the pace at which their compensation grew was also higher year-on-year, according ...